Advertisement
Canada markets open in 2 hours 27 minutes
  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CAD/USD

    0.7323
    -0.0000 (-0.00%)
     
  • CRUDE OIL

    84.07
    +0.50 (+0.60%)
     
  • Bitcoin CAD

    87,579.18
    +879.33 (+1.01%)
     
  • CMC Crypto 200

    1,386.34
    -10.19 (-0.73%)
     
  • GOLD FUTURES

    2,359.80
    +17.30 (+0.74%)
     
  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • NASDAQ futures

    17,736.00
    +168.50 (+0.96%)
     
  • VOLATILITY

    15.64
    +0.27 (+1.76%)
     
  • FTSE

    8,115.97
    +37.11 (+0.46%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6823
    +0.0002 (+0.03%)
     

A Look at Vertex Pharmaceuticals’ Operational Performance

A Look at Vertex Pharmaceuticals’ Operational Performance

How Is Vertex Pharmaceuticals Positioned in October? Vertex Pharmaceuticals’ (VRTX) cost of sales was $104.38 million in the second quarter of 2018 compared to $71.2 million in the second quarter of 2017. It incurred selling, general, and administrative expenses of $137.3 million in the second quarter of 2018 compared to $127.25 million in the second quarter of 2017.